市場調査レポート

商品コード

ヒト血小板溶解液市場の2030年までの予測：薬剤タイプ、投与経路、流通チャネル、エンドユーザー、地域別の世界分析

Human Platelet Lysate Market Forecasts to 2030 - Global Analysis By Drug Type, Route of Administration, Distribution Channel, End User and By Geography

出版日: 2024年01月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 610,008円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 771,697円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 933,386円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,102,425円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.99円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界のヒト血小板溶解液市場は2023年に5,375万米ドルを占め、予測期間中にCAGR 5.9％で成長し、2030年には8,029万米ドルに達すると予測されています。

ヒト血小板溶解液（HPL）は、ヒト血小板由来の細胞培養サプリメントです。血小板由来成長因子（PDGF）、トランスフォーミング成長因子ベータ（TGF-B）、インスリン様成長因子（IGF）などの成長因子や、細胞の生存を促進し組織再生を刺激する様々なタンパク質を含んでいます。さらに、ウシ胎児血清（FBS）のような従来の細胞培養用サプリメントに比べ、数多くの利点があります。HPLに対する需要の高まりは、その安全性、効率性、倫理的配慮など、いくつかの促進要因に起因しています。

National Library of Medicineに掲載されたデータによると、ヒト血小板溶解液（hPL）の代替オプションである牛胎児血清よりも、ヒト血小板溶解液（hPL）の方が製造コストが高いと述べられています。

細胞培養用途での需要の増加

ヒト血小板溶解液は、細胞の成長と増殖に不可欠な成長因子とサイトカインを豊富に含むことで有名であり、従来の血清ベースの培地に代わる優れた選択肢として浮上してきました。細胞増殖をサポートし、細胞特性を維持し、組織再生を促進するその能力は、再生医療、幹細胞研究、組織工学における採用の増加につながっています。さらに、個別化医療、細胞を用いた治療法、細胞培養を利用した創薬の進歩への注目の高まりは、ヒト血小板溶解液の必要性をさらに高めています。そのため、市場の成長が促進されるであろう。

高い製造コスト

ヒト血小板溶解液は、採取、処理、品質管理を含む複雑な製造工程を経るため、従来の血清ベースの培地と比較して製造コストが高くなります。このようなコスト高により、細胞培養用途で広く商業的に使用するための手頃な価格と入手しやすさが制限され、その採用が妨げられる可能性があります。その結果、市場拡大の妨げとなります。

再生医療における進歩

ヒト血小板溶解液は、細胞増殖や組織再生に不可欠な成長因子やサイトカインを豊富に含んでおり、再生療法の要求に完全に合致しています。再生医療が進化を続ける中、HPLは細胞培養において重要な補助剤として登場し、細胞増殖をサポートし、組織再生に必要な細胞特性を維持します。さらに、創傷治癒を促進し、組織修復を刺激し、細胞ベースの治療法の開発を助けるその能力は、ヒト血小板溶解液を再生医療応用における貴重な成分として位置づけています。

汚染リスク

牛胎児血清（FBS）と比較して異種コンタミネーションは減少しているもの、ヒト血小板溶解液にはヒト由来製品からの病原体伝播の潜在的リスクがあります。細菌やウィルスのような汚染物質は、ヒト血小板溶解液の品質と安全性を損なう可能性があり、研究および臨床環境における細胞培養アプリケーションの適合性に影響を与えます。そのため、市場拡大の大きな障壁となっています。

COVID-19の影響

COVID-19パンデミックは当初、ヘルスケア部門の混乱と献血制限を引き起こし、HPL製造のための原材料の入手可能性に影響を与えました。サプライチェーンの混乱と検査室活動の減少は、HPLの製造と流通に支障をきたしました。しかし、パンデミックは細胞ベースの治療の重要性を浮き彫りにし、HPLが重要な役割を果たす再生医療や細胞培養用途への関心を高めました。ヘルスケア部門が適応するにつれて、細胞ベースの治療法に対する研究の重点が高まり、HPLのさらなる需要を促進する可能性があるため、市場は復活しました。

予測期間中、ヘパリンベースのヒト血小板溶解液セグメントが最大になると予想される

ヘパリンベースのヒト血小板溶解液セグメントが最大のシェアを占めると推定されます。ヘパリンは、血小板採取およびHPL製造中の凝固を防止し、血小板の完全性と生物活性の維持を保証する役割を果たします。この特殊なHPLは、細胞の成長、増殖、生存性をサポートすることで、細胞培養用途に利点をもたらします。ヘパリンの配合はHPLの機能性を高め、再生医療、幹細胞研究、組織工学など、細胞培養の最適な結果を得るために血小板の生理活性を維持することが不可欠な様々な生物医学分野で特に有益です。

病院薬局セグメントは予測期間中最も高いCAGRが見込まれる

病院薬局セグメントは予測期間中に有利な成長を遂げると予測されています。病院薬局は、医療施設、臨床医、研究者にヒト血小板溶解製剤を提供する重要な仲介役です。これらの薬局は、再生医療、細胞治療、研究などの様々な医療用途にヒト血小板溶解液を供給する上で極めて重要な役割を果たしています。さらに、これらの薬局はヒト血小板溶解液製品の可用性、品質、タイムリーな流通を保証し、臨床現場や病院内の研究室での使用を促進しています。

最大のシェアを占める地域

アジア太平洋地域は、生物医学研究活動の活発化、再生医療への投資の増加、細胞ベースの治療への注目の高まりにより、予測期間中に最大の市場シェアを占めました。中国、日本、韓国、インドなどの国々は、医療インフラや研究イニシアチブの進歩を活用し、HPL市場の成長に大きく貢献しています。さらに、この地域の急成長するバイオ医薬品産業は、個別化医療と再生療法に重点を置くことと相まって、HPL採用の大きな機会を提供し、アジア太平洋地域を多様な生物医学用途におけるHPL利用の重要な拠点として形成しています。

CAGRが最も高い地域：

北米は、高度なヘルスケアインフラ、堅調なバイオ医薬品産業、生物医学研究への多額の投資により、予測期間中に収益性の高い成長が見られると予想されます。個別化医療が重視され、細胞ベースの治療に対する需要が高まっていることが、さまざまな生物医学用途でのHPLの利用を後押ししています。さらに北米は、最先端の研究開発と、生物医学研究や臨床の場でHPLを広く採用するための強力な基盤によって特徴付けられる、重要な地域となっています。

無料のカスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場企業の包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他の欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他のアジア太平洋
南米
- アルゼンチン
- ブラジル
- チリ
- その他の南米
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他の中東・アフリカ

第10章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第11章企業プロファイル

Abbott Laboratories
Astrazeneca Plc.
Acella Pharmaceuticals LLC
Cipla Limited
Glenmark Pharmaceuticals Limited
Dabur India Ltd
Johnson and Johnson
Glenmark Pharmaceuticals Limited
Merck KGaA
Pfizer Inc.
Novartis International AG
Sanofi SA
Vernalis plc
Aurobindo Pharma Ltd
The Himalaya Drug Company
Beckman Coulter Inc.
Sun Pharmaceutical Industries Ltd.
Reckitt Benckiser Group PLC
Acadia Pharmaceuticals Inc.
Biocon

図表

List of Tables

Table 1 Global Human Platelet Lysate Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Human Platelet Lysate Market Outlook, By Drug Type (2021-2030) ($MN)
Table 3 Global Human Platelet Lysate Market Outlook, By Heparin-based Human Platelet Lysate (2021-2030) ($MN)
Table 4 Global Human Platelet Lysate Market Outlook, By Heparin-free Human Platelet Lysate (2021-2030) ($MN)
Table 5 Global Human Platelet Lysate Market Outlook, By Other Types (2021-2030) ($MN)
Table 6 Global Human Platelet Lysate Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 7 Global Human Platelet Lysate Market Outlook, By Oral (2021-2030) ($MN)
Table 8 Global Human Platelet Lysate Market Outlook, By Inhalational (2021-2030) ($MN)
Table 9 Global Human Platelet Lysate Market Outlook, By Other Routes of Administration (2021-2030) ($MN)
Table 10 Global Human Platelet Lysate Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 11 Global Human Platelet Lysate Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 12 Global Human Platelet Lysate Market Outlook, By Drug Store (2021-2030) ($MN)
Table 13 Global Human Platelet Lysate Market Outlook, By Retail Store (2021-2030) ($MN)
Table 14 Global Human Platelet Lysate Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 15 Global Human Platelet Lysate Market Outlook, By End User (2021-2030) ($MN)
Table 16 Global Human Platelet Lysate Market Outlook, By Therapeutic (2021-2030) ($MN)
Table 17 Global Human Platelet Lysate Market Outlook, By Research and Academic Institutions (2021-2030) ($MN)
Table 18 Global Human Platelet Lysate Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
Table 19 Global Human Platelet Lysate Market Outlook, By Other End Users (2021-2030) ($MN)
Table 20 North America Human Platelet Lysate Market Outlook, By Country (2021-2030) ($MN)
Table 21 North America Human Platelet Lysate Market Outlook, By Drug Type (2021-2030) ($MN)
Table 22 North America Human Platelet Lysate Market Outlook, By Heparin-based Human Platelet Lysate (2021-2030) ($MN)
Table 23 North America Human Platelet Lysate Market Outlook, By Heparin-free Human Platelet Lysate (2021-2030) ($MN)
Table 24 North America Human Platelet Lysate Market Outlook, By Other Types (2021-2030) ($MN)
Table 25 North America Human Platelet Lysate Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 26 North America Human Platelet Lysate Market Outlook, By Oral (2021-2030) ($MN)
Table 27 North America Human Platelet Lysate Market Outlook, By Inhalational (2021-2030) ($MN)
Table 28 North America Human Platelet Lysate Market Outlook, By Other Routes of Administration (2021-2030) ($MN)
Table 29 North America Human Platelet Lysate Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 30 North America Human Platelet Lysate Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 31 North America Human Platelet Lysate Market Outlook, By Drug Store (2021-2030) ($MN)
Table 32 North America Human Platelet Lysate Market Outlook, By Retail Store (2021-2030) ($MN)
Table 33 North America Human Platelet Lysate Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 34 North America Human Platelet Lysate Market Outlook, By End User (2021-2030) ($MN)
Table 35 North America Human Platelet Lysate Market Outlook, By Therapeutic (2021-2030) ($MN)
Table 36 North America Human Platelet Lysate Market Outlook, By Research and Academic Institutions (2021-2030) ($MN)
Table 37 North America Human Platelet Lysate Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
Table 38 North America Human Platelet Lysate Market Outlook, By Other End Users (2021-2030) ($MN)
Table 39 Europe Human Platelet Lysate Market Outlook, By Country (2021-2030) ($MN)
Table 40 Europe Human Platelet Lysate Market Outlook, By Drug Type (2021-2030) ($MN)
Table 41 Europe Human Platelet Lysate Market Outlook, By Heparin-based Human Platelet Lysate (2021-2030) ($MN)
Table 42 Europe Human Platelet Lysate Market Outlook, By Heparin-free Human Platelet Lysate (2021-2030) ($MN)
Table 43 Europe Human Platelet Lysate Market Outlook, By Other Types (2021-2030) ($MN)
Table 44 Europe Human Platelet Lysate Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 45 Europe Human Platelet Lysate Market Outlook, By Oral (2021-2030) ($MN)
Table 46 Europe Human Platelet Lysate Market Outlook, By Inhalational (2021-2030) ($MN)
Table 47 Europe Human Platelet Lysate Market Outlook, By Other Routes of Administration (2021-2030) ($MN)
Table 48 Europe Human Platelet Lysate Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 49 Europe Human Platelet Lysate Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 50 Europe Human Platelet Lysate Market Outlook, By Drug Store (2021-2030) ($MN)
Table 51 Europe Human Platelet Lysate Market Outlook, By Retail Store (2021-2030) ($MN)
Table 52 Europe Human Platelet Lysate Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 53 Europe Human Platelet Lysate Market Outlook, By End User (2021-2030) ($MN)
Table 54 Europe Human Platelet Lysate Market Outlook, By Therapeutic (2021-2030) ($MN)
Table 55 Europe Human Platelet Lysate Market Outlook, By Research and Academic Institutions (2021-2030) ($MN)
Table 56 Europe Human Platelet Lysate Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
Table 57 Europe Human Platelet Lysate Market Outlook, By Other End Users (2021-2030) ($MN)
Table 58 Asia Pacific Human Platelet Lysate Market Outlook, By Country (2021-2030) ($MN)
Table 59 Asia Pacific Human Platelet Lysate Market Outlook, By Drug Type (2021-2030) ($MN)
Table 60 Asia Pacific Human Platelet Lysate Market Outlook, By Heparin-based Human Platelet Lysate (2021-2030) ($MN)
Table 61 Asia Pacific Human Platelet Lysate Market Outlook, By Heparin-free Human Platelet Lysate (2021-2030) ($MN)
Table 62 Asia Pacific Human Platelet Lysate Market Outlook, By Other Types (2021-2030) ($MN)
Table 63 Asia Pacific Human Platelet Lysate Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 64 Asia Pacific Human Platelet Lysate Market Outlook, By Oral (2021-2030) ($MN)
Table 65 Asia Pacific Human Platelet Lysate Market Outlook, By Inhalational (2021-2030) ($MN)
Table 66 Asia Pacific Human Platelet Lysate Market Outlook, By Other Routes of Administration (2021-2030) ($MN)
Table 67 Asia Pacific Human Platelet Lysate Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 68 Asia Pacific Human Platelet Lysate Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 69 Asia Pacific Human Platelet Lysate Market Outlook, By Drug Store (2021-2030) ($MN)
Table 70 Asia Pacific Human Platelet Lysate Market Outlook, By Retail Store (2021-2030) ($MN)
Table 71 Asia Pacific Human Platelet Lysate Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 72 Asia Pacific Human Platelet Lysate Market Outlook, By End User (2021-2030) ($MN)
Table 73 Asia Pacific Human Platelet Lysate Market Outlook, By Therapeutic (2021-2030) ($MN)
Table 74 Asia Pacific Human Platelet Lysate Market Outlook, By Research and Academic Institutions (2021-2030) ($MN)
Table 75 Asia Pacific Human Platelet Lysate Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
Table 76 Asia Pacific Human Platelet Lysate Market Outlook, By Other End Users (2021-2030) ($MN)
Table 77 South America Human Platelet Lysate Market Outlook, By Country (2021-2030) ($MN)
Table 78 South America Human Platelet Lysate Market Outlook, By Drug Type (2021-2030) ($MN)
Table 79 South America Human Platelet Lysate Market Outlook, By Heparin-based Human Platelet Lysate (2021-2030) ($MN)
Table 80 South America Human Platelet Lysate Market Outlook, By Heparin-free Human Platelet Lysate (2021-2030) ($MN)
Table 81 South America Human Platelet Lysate Market Outlook, By Other Types (2021-2030) ($MN)
Table 82 South America Human Platelet Lysate Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 83 South America Human Platelet Lysate Market Outlook, By Oral (2021-2030) ($MN)
Table 84 South America Human Platelet Lysate Market Outlook, By Inhalational (2021-2030) ($MN)
Table 85 South America Human Platelet Lysate Market Outlook, By Other Routes of Administration (2021-2030) ($MN)
Table 86 South America Human Platelet Lysate Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 87 South America Human Platelet Lysate Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 88 South America Human Platelet Lysate Market Outlook, By Drug Store (2021-2030) ($MN)
Table 89 South America Human Platelet Lysate Market Outlook, By Retail Store (2021-2030) ($MN)
Table 90 South America Human Platelet Lysate Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 91 South America Human Platelet Lysate Market Outlook, By End User (2021-2030) ($MN)
Table 92 South America Human Platelet Lysate Market Outlook, By Therapeutic (2021-2030) ($MN)
Table 93 South America Human Platelet Lysate Market Outlook, By Research and Academic Institutions (2021-2030) ($MN)
Table 94 South America Human Platelet Lysate Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
Table 95 South America Human Platelet Lysate Market Outlook, By Other End Users (2021-2030) ($MN)
Table 96 Middle East & Africa Human Platelet Lysate Market Outlook, By Country (2021-2030) ($MN)
Table 97 Middle East & Africa Human Platelet Lysate Market Outlook, By Drug Type (2021-2030) ($MN)
Table 98 Middle East & Africa Human Platelet Lysate Market Outlook, By Heparin-based Human Platelet Lysate (2021-2030) ($MN)
Table 99 Middle East & Africa Human Platelet Lysate Market Outlook, By Heparin-free Human Platelet Lysate (2021-2030) ($MN)
Table 100 Middle East & Africa Human Platelet Lysate Market Outlook, By Other Types (2021-2030) ($MN)
Table 101 Middle East & Africa Human Platelet Lysate Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 102 Middle East & Africa Human Platelet Lysate Market Outlook, By Oral (2021-2030) ($MN)
Table 103 Middle East & Africa Human Platelet Lysate Market Outlook, By Inhalational (2021-2030) ($MN)
Table 104 Middle East & Africa Human Platelet Lysate Market Outlook, By Other Routes of Administration (2021-2030) ($MN)
Table 105 Middle East & Africa Human Platelet Lysate Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 106 Middle East & Africa Human Platelet Lysate Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 107 Middle East & Africa Human Platelet Lysate Market Outlook, By Drug Store (2021-2030) ($MN)
Table 108 Middle East & Africa Human Platelet Lysate Market Outlook, By Retail Store (2021-2030) ($MN)
Table 109 Middle East & Africa Human Platelet Lysate Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 110 Middle East & Africa Human Platelet Lysate Market Outlook, By End User (2021-2030) ($MN)
Table 111 Middle East & Africa Human Platelet Lysate Market Outlook, By Therapeutic (2021-2030) ($MN)
Table 112 Middle East & Africa Human Platelet Lysate Market Outlook, By Research and Academic Institutions (2021-2030) ($MN)
Table 113 Middle East & Africa Human Platelet Lysate Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
Table 114 Middle East & Africa Human Platelet Lysate Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC24735

According to Stratistics MRC, the Global Human Platelet Lysate Market is accounted for $53.75 million in 2023 and is expected to reach $80.29 million by 2030 growing at a CAGR of 5.9% during the forecast period. Human Platelet Lysate (HPL) is a cell culture supplement derived from human blood platelets. It contains growth factors like platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-B), insulin-like growth factor (IGF), and various other proteins that promote cell survival and stimulate tissue regeneration. Moreover, it offers numerous advantages over traditional cell culture supplements like foetal bovine serum (FBS). The growing demand for HPL can be attributed to several driving factors, including its safety, efficiency, and ethical considerations.

According to data published on National Library of Medicine, stated that human platelet lysate (hPL) has higher production cost than foetal bovine serum, which is an alternative option of human platelet lysate (hPL).

Market Dynamics:

Driver:

Increasing demand in cell culture applications

Human platelet lysate, renowned for its rich composition of growth factors and cytokines essential for cell growth and proliferation, has emerged as a superior alternative to traditional serum-based media. Its ability to support cell expansion, maintain cellular properties, and promote tissue regeneration has led to increased adoption in regenerative medicine, stem cell research, and tissue engineering. Moreover, the heightened focus on personalised medicine, cell-based therapies, and advancements in drug discovery utilising cell cultures further amplifies the need for human platelet lysate. Therefore, it will propel market growth.

Restraint:

High production costs

The complex manufacturing process involving the collection, processing, and quality control measures for human platelet lysate results in elevated production expenses compared to traditional serum-based media. These higher costs limit its affordability and accessibility for widespread commercial use in cell culture applications, potentially hindering its adoption. As a result, it will hamper market expansion.

Opportunity:

Advancements in regenerative medicine

The human platelet lysate's rich composition of growth factors and cytokines essential for cell growth and tissue regeneration aligns perfectly with the requirements of regenerative therapies. As regenerative medicine continues to evolve, HPL emerges as a crucial supplement in cell culture, supporting cell proliferation and maintaining cellular properties necessary for tissue regeneration. Furthermore, its ability to enhance wound healing, stimulate tissue repair, and aid in the development of cell-based therapies positions human platelet lysate as a valuable component in regenerative medicine applications.

Threat:

Contamination risks

Despite reduced xenogeneic contamination compared to foetal bovine serum (FBS), human platelet lysate carries the potential risk of pathogen transmission from human-derived products. Contaminants, such as bacteria or viruses, could compromise the quality and safety of human platelet lysate, impacting its suitability for cell culture applications in research and clinical settings. Hence, it acts as a significant barrier to market expansion.

COVID-19 Impact

The COVID-19 pandemic initially caused disruptions in the healthcare sector and restrictions on blood donations, which affected the availability of raw materials for HPL production. Supply chain disruptions and reduced laboratory activities hindered its manufacturing and distribution. However, the pandemic underscored the importance of cell-based therapies, boosting interest in regenerative medicine and cell culture applications where HPL plays a crucial role. As the healthcare sector adapted, the market witnessed a resurgence due to increased research focus on cell-based treatments, potentially driving further demand for HPL.

The heparin-based human platelet lysate segment is expected to be the largest during the forecast period

The heparin-based human platelet lysate segment is estimated to hold the largest share. Heparin serves to prevent clotting during platelet collection and HPL production, ensuring the maintenance of platelet integrity and bioactivity. This specialised variant of HPL offers advantages in cell culture applications by supporting cell growth, proliferation, and viability. The inclusion of heparin enhances the functionality of HPL, making it particularly beneficial in various biomedical fields, including regenerative medicine, stem cell research, and tissue engineering, where uninterrupted platelet bioactivity is essential for optimal cell culture outcomes.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

The hospital pharmacies segment is anticipated to have lucrative growth during the forecast period. Hospital pharmacies serve as crucial intermediaries, providing human platelet lysate products to healthcare facilities, clinicians, and researchers. These pharmacies play a pivotal role in supplying human platelet lysate for various medical applications, including regenerative medicine, cell therapy, and research endeavours. Moreover, they ensure the availability, quality, and timely distribution of human platelet lysate products, facilitating their use in clinical settings and research laboratories within hospitals.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to rising biomedical research activities, increasing investments in regenerative medicine, and a growing focus on cell-based therapies. Countries such as China, Japan, South Korea, and India are prominent contributors to HPL market growth, leveraging advancements in healthcare infrastructure and research initiatives. Furthermore, the region's burgeoning biopharmaceutical industry, combined with the emphasis on personalised medicine and regenerative therapies, offers substantial opportunities for HPL adoption, shaping the Asia-Pacific region as a significant hub for HPL utilisation in diverse biomedical applications.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period due to advanced healthcare infrastructure, a robust biopharmaceutical industry, and substantial investments in biomedical research. Growing emphasis on personalised medicine and the escalating demand for cell-based therapies bolster the utilisation of HPL in various biomedical applications. Furthermore, North America stands as a key region, characterised by its cutting-edge developments and a strong foundation for the widespread adoption of HPL in biomedical research and clinical settings.

Key players in the market:

Some of the key players in the Human Platelet Lysate Market include Abbott Laboratories, Astrazeneca Plc., Acella Pharmaceuticals LLC, Cipla Limited, Glenmark Pharmaceuticals Limited, Dabur India Ltd, Johnson and Johnson, Glenmark Pharmaceuticals Limited, Merck KGaA, Pfizer Inc., Novartis International AG, Sanofi SA, Vernalis plc, Aurobindo Pharma Ltd, The Himalaya Drug Company, Beckman Coulter Inc., Sun Pharmaceutical Industries Ltd., Reckitt Benckiser Group PLC, Acadia Pharmaceuticals Inc. and Biocon.

Key Developments:

In June 2023, PL BioScience GmbH entered into a Patent License and Assignment Agreement with French company Macopharma S.A.S., granting PL BioScience a worldwide license under Macopharma's patents and introducing PL BioScience to Macopharma's HPL customers for future orders.

In August 2022, StemCyte, Inc. obtained approval from U.S. FDA for their Phase II clinical trial for Post-COVID Syndrome using umbilical cord blood stem cell therapy.

In June 2021, Captivate Bio has signed a partnership agreement with PL BioScience GmbH to exclusively distribute ELAREM human platelet lysate products in the US and Canada, expanding their HPL offerings and enhancing PL BioScience's market presence in North America.

Drug Types Covered:

Heparin-based Human Platelet Lysate
Heparin-free Human Platelet Lysate
Other Types

Route of Administrations Covered:

Oral
Inhalational
Other Routes of Administration

Distribution Channels Covered:

Hospital Pharmacies
Drug Store
Retail Store
Online Pharmacies

End Users Covered:

Therapeutic
Pharmaceutical and Biotechnology Companies
Research and Academic Institutions
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Human Platelet Lysate Market, By Drug Type

5.1 Introduction
5.2 Heparin-based Human Platelet Lysate
5.3 Heparin-free Human Platelet Lysate
5.4 Other Types

6 Global Human Platelet Lysate Market, By Route of Administration

6.1 Introduction
6.2 Oral
6.3 Inhalational
6.4 Other Routes of Administration

7 Global Human Platelet Lysate Market, By Distribution Channel

7.1 Introduction
7.2 Hospital Pharmacies
7.3 Drug Store
7.4 Retail Store
7.5 Online Pharmacies

8 Global Human Platelet Lysate Market, By End User

8.1 Introduction
8.2 Therapeutic
8.3 Research and Academic Institutions
8.4 Pharmaceutical and Biotechnology Companies
8.5 Other End Users

9 Global Human Platelet Lysate Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Abbott Laboratories
11.2 Astrazeneca Plc.
11.3 Acella Pharmaceuticals LLC
11.4 Cipla Limited
11.5 Glenmark Pharmaceuticals Limited
11.6 Dabur India Ltd
11.7 Johnson and Johnson
11.8 Glenmark Pharmaceuticals Limited
11.9 Merck KGaA
11.10 Pfizer Inc.
11.11 Novartis International AG
11.12 Sanofi SA
11.13 Vernalis plc
11.14 Aurobindo Pharma Ltd
11.15 The Himalaya Drug Company
11.16 Beckman Coulter Inc.
11.17 Sun Pharmaceutical Industries Ltd.
11.18 Reckitt Benckiser Group PLC
11.19 Acadia Pharmaceuticals Inc.
11.20 Biocon